

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/731,657	03/12/2001	Caroline Osterhoff	35-196	1569
75	90 03/13/2002			
Nixon & Vanderhye P.C. 8th Floor 1100 N. Glebe Rd			EXAMINER	
			ULM, JOHN D	
Arlington, VA 22201			ART UNIT	PAPER NUMBER
			1646	
			DATE MAILED: 03/13/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/731,657

Applicant(s)

Osterhoff et al.

Examiner

John Ulm

Art Unit **1646**

The MAILING DATE of this communication appears on the cover sheet with the correspondence address				
Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH(S) FROM			
 Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communic If the period for reply specified above is less than thirty (30) days 	eation.			
communication.	period will apply and will expire SIX (6) MONTHS from the mailing date of this			
 Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b). 	y statute, cause the application to become ABANDONED (35 U.S.C. § 133). e mailing date of this communication, even if timely filed, may reduce any			
Status				
1) X Responsive to communication(s) filed on <u>Dec 8, 20</u>	000			
2a) ☐ This action is FINAL . 2b) ☒ This ac	tion is non-final.			
3) Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is orte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims				
4) 🗓 Claim(s) <u>1-30</u>	is/are pending in the application.			
4a) Of the above, claim(s)	is/are withdrawn from consideration.			
5)	is/are allowed.			
6) Claim(s)	is/are rejected.			
7)	is/are objected to.			
8) 🗓 Claims <u>1-30</u>	are subject to restriction and/or election requirement.			
Application Papers				
9) \square The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/are	objected to by the Examiner.			
11) \square The proposed drawing correction filed on	is: a)□ approved b)□ disapproved.			
12) \square The oath or declaration is objected to by the Exam	iner.			
Priority under 35 U.S.C. § 119				
13) \square Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).			
a) \square All b) \square Some* c) \square None of:				
1. \square Certified copies of the priority documents have	re been received.			
2. \square Certified copies of the priority documents have	re been received in Application No			
 Copies of the certified copies of the priority d application from the International Bure *See the attached detailed Office action for a list of th 	ocuments have been received in this National Stage au (PCT Rule 17.2(a)).			
14) Acknowledgement is made of a claim for domestic				
	p. 10.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10, 0.10			
Attachment(s) 5) Notice of References Cited (PTO-892)	19)			
Notice of Draftsperson's Patent Drawing Review (PTO-948)	18) Interview Summary (PTO-413) Paper No(s).			
6) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 7) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:				

Art Unit: 1646

Claims 1 to 30 are pending in the instant application. Claims 1 to 5, 17, 21, 23, 26, 27 and 30 have been amended as requested by Applicant in Paper Number 4, filed 08 December of 2000.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1 to 5, 17, 21 and 22, drawn to a protein, classified in class 530, subclass 350.
- II. Claims 6 to 14, 19 and 20, drawn to a nucleic acid, a vector and cell containing that nucleic acid and method of use, classified in class 435, subclass 69.1.
- III. Claims 15, 16 and 18, drawn to an antibody, classified in class 530, subclass 388.22.
- IV. Claims 23 to 25, drawn to a binding assay, classified in class 436, subclass 501.
- V. Claims 26 and 28, drawn to a method of treatment by administering a compound of unspecified constitution which is a receptor agonist, classified in class undeterminable, subclass undeterminable.
- VI. Claims 27 and 29, drawn to a method of treatment by administering a compound of unspecified constitution which is a receptor antagonist classified in class undeterminable, subclass undeterminable.
- VII. Claim 30, drawn to an immunoassay, classified in class 436, subclass 6.

The inventions are distinct, each from the other because:

The protein that is invention I, the nucleic acid that is invention II, the antibody that is invention III, the agonist of unspecified constitution employed in invention V and the antagonist

Application/Control Number: 09/731,657

Art Unit: 1646

of unspecified constitution that is employed in invention VI are five structurally and functionally different chemical compounds each of which can be made and used without any one or more of the other compounds. Lack of unity is shown because these compounds lack a common utility which is based upon a common structural feature which has been identified as the basis for that common utility.

Invention I is related to each inventions IV and VII as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the receptor protein as claimed could be used to detect the presence of a ligand thereto in a sample as claimed in invention IV, which is a process that is materially different from a method of treatment that is invention VII.

Inventions V and VI are unrelated to one another or to any of inventions I to IV and VII.

Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case inventions V and VI are not capable of use together since they are intended to have opposing effects. The methods that are inventions V and VI are not related to any of inventions I to III as either method of making or method of using any of the claimed products.

Art Unit: 1646

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1800